Work in the ScleroLab is patient-oriented, bench-to-bedside, and encompasses several approaches, ranging from genetics and functional genomics to vascular biology, cellular immunology, metabolic studies, molecular and live imaging, and matrix biology. We deploy these approaches to discover, validate, and develop novel targets for diagnosis, precision medicine, and targeted human therapies. Our current research projects are listed below.
DAMPs: Damage-Associated Molecular Patterns Driving Fibrosis Progression in Scleroderma
(Sponsor: NIH; R01 AR074997)